5 Park Plaza
Suite 1750
Irvine, CA 92614
United States
(949) 354-6499
https://www.aeonbiopharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 10
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Marc Forth | Principal Financial Officer, President, CEO & Director | 948,75k | N/A | 1971 |
Mr. Alex Wilson | Executive VP, Chief Legal Officer & Corporate Secretary | 517,4k | N/A | 1987 |
Dr. Chad K. Oh M.D. | Chief Medical Officer | 561k | N/A | 1959 |
Ms. Jennifer Sy | Principal Accounting Officer | N/A | N/A | 1985 |
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
AEON Biopharma, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.